DUPIXENT Market Drug Insight and Market Forecast - 2032

DUPIXENT Market Drug Insight and Market Forecast − 2032

“DUPIXENT Market Drug Insight and Market Forecast – 2032” report provides comprehensive insights about DUPIXENT for Atopic Dermatitis (AD) in the seven major markets. A detailed picture of the DUPIXENT for atopic dermatitis in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in this report along with a detailed description of the DUPIXENT for atopic dermatitis. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the DUPIXENT market forecast analysis for atopic dermatitis in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in atopic dermatitis.

Drug Summary

DUPIXENT is a fully-human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) proteins and is not an immunosuppressant. Data from DUPIXENT clinical trials have shown that IL-4 and IL-13 are key drivers of the type 2 inflammation that plays a major role in AD, asthma, and chronic rhinosinusitis with nasal polyposis (CRSwNP).

The drug was invented using Regeneron’s VelocImmune technology that utilizes a proprietary genetically engineered mouse platform endowed with a genetically-humanized immune system to produce optimized fully-human antibodies.

DUPIXENT has been approved for adolescents and adults with moderate-to-severe AD, asthma and/or in adults with CRSwNP in several countries around the world, including the US, where DUPIXENT is also approved for children with moderate-to-severe AD. DUPIXENT is currently approved in more than 60 countries, and more than 190,000 patients have been treated globally. Regeneron and Sanofi are jointly developing dupilumab under a global collaboration agreement since January 2018.

Scope of the Report

The report provides insights into:

A comprehensive product overview including the DUPIXENT description, mechanism of action, dosage and administration, research and development activities in atopic dermatitis.

Elaborated details on DUPIXENT regulatory milestones and other development activities have been provided in this report.

The report also highlights the DUPIXENT research and development activities in atopic dermatitis across the United States, Europe and Japan.

The report also covers the patents information with expiry timeline around DUPIXENT.

The report contains forecasted sales of for atopic dermatitis till 2032.

Comprehensive coverage of the late-stage emerging therapies for atopic dermatitis.

The report also features the SWOT analysis with analyst views for DUPIXENT in atopic dermatitis.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

DUPIXENT Analytical Perspective by DelveInsight

In-depth DUPIXENT Market Assessment

This report provides a detailed market assessment of DUPIXENT for atopic dermatitis in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

DUPIXENT Clinical Assessment

The report provides the clinical trials information of DUPIXENT for atopic dermatitis covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

In the coming years, the market scenario for atopic dermatitis is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.

The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence DUPIXENT dominance.

Other emerging products for atopic dermatitis are expected to give tough market competition to DUPIXENT and launch of late-stage emerging therapies in the near future will significantly impact the market.

A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of DUPIXENT in atopic dermatitis.

Our in-depth analysis of the forecasted sales data of DUPIXENT from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the DUPIXENT in atopic dermatitis.

Key Questions

What is the product type, route of administration and mechanism of action of DUPIXENT?

What is the clinical trial status of the study related to DUPIXENT in atopic dermatitis and study completion date?

What are the key collaborations, mergers and acquisitions, licensing and other activities related to the DUPIXENT development?

What are the key designations that have been granted to DUPIXENT for atopic dermatitis?

What is the forecasted market scenario of DUPIXENT for atopic dermatitis?

What are the forecasted sales of DUPIXENT in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?

What are the other emerging products available and how are these giving competition to DUPIXENT for atopic dermatitis?

Which are the late-stage emerging therapies under development for the treatment of atopic dermatitis?